Pyrilutamide (development code KX-826) is a topical androgen receptor antagonist under development by Kintor Pharmaceuticals for the treatment of male pattern hair loss.
It has been shown to be safe and effective in a US phase-2 clinical trial.
Unlike Minoxidil, it does not decrease systemic androgen levels or cause side effects such as libido loss or erectile dysfunction. It also has a better tolerability profile than oral 5-alpha reductase inhibitors such as finasteride.
Buy pyrilutamide 0.5% solution is a new topical drug that shows promise as an effective treatment for male pattern baldness. It works by blocking DHT function and preventing testosterone from binding to the hair follicle. This reduces androgen levels in the scalp, which helps to increase hair growth.
The development of this drug by Kintor Pharmaceuticals is very exciting.
It also appears to have fewer side effects, such as decreased libido and erectile dysfunction.
Kintor Pharmaceuticals is currently in phase II for Androgenic Alopecia, but the company’s latest press release indicates that the US phase 3 trial is set to start next year (2021). This is good news for patients who are waiting for a new and more effective drug against alopecia.
Kintor Pharmaceutical’s drug is called pyrilutamide (development code KX-826), and it is an androgen receptor antagonist. It has completed a randomized, double-blind, placebo-controlled clinical trial in China.
Pyrilutamide (KX-826) is a topical anti-androgen with strong binding affinity for the DHT receptor. The drug is undergoing phase-2 clinical trials in the US and China. It is a potential first-in-class oral AR antagonist and has the potential to significantly reduce hair loss in balding men with less side effects than existing treatments.
Kintor Pharmaceutical has received FDA approval to begin the randomized, double-blind, placebo-controlled phase-2 trial of KX-826 in male subjects with AGA. The study will assess the efficacy of buy pyrilutamide from MV Supplements at 0.5% twice daily on the target area of the scalp.
The company carries out research and development operations to discover treatment for diseases including COVID-19, prostate cancer, breast cancer, liver cancer and leukaemia. It also carries out marketing and distribution activities to carters across Taiwan, Hong Kong, China, the United States, Australia and Brazil. It is focused on the discovery of small molecule therapeutics targeting disease areas with few effective therapies. The company currently has several clinical-stage products including Proxalutamide, Destorsertib and KX-826.
Pyrilutamide has a high affinity to the androgen receptor and is therefore able to significantly reduce DHT levels in hair follicles. It is a potential first-in-class topical treatment for androgenetic alopecia. It has been shown to be effective in reducing scalp thinning and loss in clinical trials. However, it also has some unwanted side effects, such as decreased libido and erectile dysfunction. These side effects are similar to those experienced with oral 5-alpha reductase inhibitors.
In a rare Sunday press release, Kintor Pharmaceutical of China announced the start of a phase 2 US trial for their new drug Pyrilutamide. This will be a randomized, double-blind, placebo controlled clinical study that will observe a change in non-vellus target area hair count over a 6 month period.
For more information about pyrilutamide and its status in clinical development, please refer to GlobalData’s Pyrilutamide Phase-Transition/LoA report, which is available for purchase now.
This report provides indication benchmark PTSR and LoA scores based off of 18 years of historical data.
Pyrilutamide is an antiandrogen with a high affinity for the androgen receptor. It is being researched for its potential to treat hair loss in a manner different from finasteride or minoxidil. It is currently in phase II clinical trials in the US and China.
The research into this compound its strong and proven effect of significantly reducing androgenic alopecia in balding men current treatments.
The raw material pyrilutamide used in PyriPure was tested and confirmed to be >99% pure by an independent testing lab. PyriPure is a solution of pyrilutamide in ethanol and propylene glycol and can be shipped as a non-hazardous liquid. Each bottle contains a pipette for precise application.
GlobalData’s pyrilutamide drug development and phase transition benchmark PTSR reports provide comprehensive insights for 18 years.
This information is used to create unique benchmarks, including indication benchmarks and a probability of approval score (LoA). Buy the pyrilutamide LoA report here.